MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In


News Categories




Yervoy (Ipilimumab) Disappoints in Prostate Cancer Trial

Drug fails to meet phase III endpoint (September 12)

Disappointing results have been reported from a phase III randomized, double-blind clinical trial comparing Yervoy (ipilimumab, Bristol-Myers Squibb) 10 mg/kg with placebo following radiation in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who had received prior treatment with docetaxel.

The study’s primary endpoint of overall survival (OS) did not reach statistical significance (hazard ratio = 0.85; P = 0.053). However, antitumor activity was observed across some efficacy endpoints, including progression free-survival.

The new data will be presented Sept. 28 at the 2013 European Cancer Congress.

In the intent-to-treat population, the median OS was 11.2 months for ipilimumab and 10.0 months for placebo. The 1- and 2-year survival rates for ipilimumab versus placebo were 47% versus 40%, and 26% versus 15%, respectively.

Yervoy (ipilimumab) is currently indicated for the treatment of unresectable or metastatic melanoma.

Ipilimumab is a recombinant human monoclonal antibody that blocks the cytotoxic T-lymphocyte antigen-4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activation. Ipilimumab binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80 and CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation.

Source: Bristol-Myers Squibb; September 12, 2014.

More stories